Solid Biosciences Completes IPO – Barron’s
Barron’s |
Solid Biosciences Completes IPO
Barron’s The safety of Solid’s gene therapy also is an issue following the recent resignation by Dr. James Wilson, one of the leading scientists in the field, from Solid’s scientific advisory board due to apparent concerns about the safety of Solid’s gene … |
|
CRISPR European patent cancellation highlights procedural IP pitfalls
IAM (blog) The European Patent Office’s revocation of a key patent relating to the revolutionary CRISPR technology sent shockwaves around the IP world last week. While the much-discussed ongoing US CRISPR dispute has raised fundamental questions about obviousness … The continuing CRISPR patent battle: the Broad Institute loses a key European patentLexology |
Courthouse News Service |
Stem–Cell Therapy: a Boon or a Boondoggle?
Courthouse News Service HOUSTON (CN) — Injected with 600 million stem cells grown from his own stomach fat, an elderly man said the injections stopped his Parkinson’s disease tremors and he’s now teeing up his own golf balls and competing in golf tournaments. A teenager said … |
PharmaTimes |
Scotland’s Synpromics expands gene therapy work with UCL deal
PharmaTimes Edinburgh, Scotland based Synpromics has teamed up with UCL Great Ormond Street Institute of Child Health to develop novel gene therapies for diseases affecting the haematopoietic system. This partnership further expands the firm’s activities in the … |